Iscador*P

Hackensack Meridian Health · Phase 2 active Small molecule

At a glance

Generic name	Iscador*P
Sponsor	Hackensack Meridian Health
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma (PHASE2)
A Prospective Dose Finding Study of Iscador Infusion (PHASE1, PHASE2)
Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Iscador*P CI brief — competitive landscape report
Iscador*P updates RSS · CI watch RSS
Hackensack Meridian Health portfolio CI